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Abstract
Background Hepatic artery embolisation (HAE) in patients
with hereditary haemorrhagic telangiectasia (HHT) is con-
troversial because of the associated complications and un-
proven long-term benefit. We present our results in 20 such
patients over a time span of 17 years.
Methods Staged HAE was performed using polyvinyl alco-
hol (PVA) particles and coils. Complications, clinical symp-
toms and cardiac output were assessed before and after
therapy as well as at the end of follow-up (median
92 months, range 26–208 months).
Results Two patients died within 30 days following HAE
(10 %). Four further deaths resulted from causes unrelated to
HAE. Ischaemic cholangitis, cholecystitis and focal hepatic
necrosis with biliary sepsis necessitated re-intervention in
four patients. In all but one patient, clinical symptoms
resolved with mean cardiac output falling from 11.84±
3.22 l/min pre-treatment to 8.13±2.67 l/min at the end of
follow-up (P<0.001). One patient required liver transplan-
tation for de novo symptoms of portal hypertension 4 years
after primary symptoms had been cured by HAE.
Conclusion The 30-day mortality of HAE in patients with
HHT is 10 %. The rate of complications requiring re-
intervention is 20 %. Clinical response at long-term
follow-up is satisfactory.
Key Points
• Hepatic artery embolisation (HAE) in hereditary haemor-
rhagic telangiectasia (HHT) provides long-term benefit.
• Mortalities of HAE and liver transplantation in HHT
patients are comparable.
• In HHT, complications of HAE are lower than those of
liver transplantation.
A. Chavan (*) : L. Luthe : B. Schmuck
Department of Diagnostic and Interventional Radiology,
Klinikum Oldenburg,




























Department of Radiology, Hannover Medical School,
Hannover, Germany
e-mail: Kirchhoff.Timm@mh-hannover.de
Eur Radiol (2013) 23:951–957
DOI 10.1007/s00330-012-2694-9
• Complications of HAE can be further reduced by refinement
of technique.
• Complications include ischaemic cholangitis, hepatic
necrosis, biliary sepsis and death.
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PVA Poly vinyl alcohol
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Introduction
The prevalence of hepatic involvement in hereditary hae-
morrhagic telangiectasia (HHT) has been estimated to be
between 41 % and 78 % with a clear female predominance.
Most patients are asymptomatic [1, 2]. Symptomatic hepatic
involvement that cannot be managed medically necessitates
intervention [3, 4]. Currently, liver transplantation and he-
patic artery embolisation (HAE) are the two main treatment
options. Consensus recommendations published in 2006 [3]
as well as the international guidelines published in 2009 [5]
favour liver transplantation over HAE on account of the
procedure-related complications of HAE, which may even
lead to liver transplantation [6] or death [7]. In an attempt to
define the role of HAE in the treatment algorithm of such
patients, we present the complications, clinical outcome and
the quality-of-life assessment in 20 consecutive patients
who were treated with HAE over a time span of 17 years.
Materials and methods
Between May 1991 and April 2007, 20 of the 38 patients
presenting at the Hannover Medical School or at the
Klinikum Oldenburg (teaching hospital affiliated to the
Göttingen University Medical School) having HHT with
symptomatic hepatic involvement were treated with staged
HAE after reaching an interdisciplinary consensus between
the radiologists, gastroenterologists and transplant surgeons.
Pertinent follow-up records until January 2009 were evalu-
ated. The diagnosis of HHT was made using the Curaçao
criteria [8]. At least three Curaçao criteria were present in all
patients. Informed consent was obtained from all patients.
The median follow-up period was 92 months (range 26–
208 months). Short and mid-term results in 15 of the 20
patients have been reported previously [9, 10].
The inclusion criteria were therapy-resistant right-upper-
quadrant capsular pain or abdominal angina, portal hyperten-
sion with ascites, pedal oedema and/or oesophageal varices
and a raised cardiac output exceeding 7 l/min associated with
clinical features of cardiac failure/insufficiency including early
fatigue, limitation of physical activity, dyspnoea, orthopnoea
or pedal oedema. Asymptomatic patients or those who could
successfully be treated conservatively with medical therapy
were excluded from the study. All patients fulfilling the inclu-
sion criteria underwent HAE. On account of the severity of
their symptoms, all 20 patients requested or demanded thera-
py; consequently, there were no therapy refusals.
The diagnostic workup included colour Doppler ultra-
sound of the liver as well as helical CT of the entire abdo-
men before and after therapy and at the end of follow-up.
Routine laboratory parameters as well as those specific to
the liver were recorded before and after every intervention
as well as at the end of follow-up. Cardiac output was
determined using echocardiography prior to therapy and at
the end of follow-up. In patients who died, the last cardiac
output measured prior to death was used for purposes of
statistical evaluation.
Hepatic artery embolisations in stages were carried out in
one to five sessions at intervals ranging from 1 to 15 weeks.
The intervals between the embolisation sessions were deter-
mined by the time required for the patient to recover from
the previous embolisation as well as by the time required for
the hepatic parameters to return to pre-embolisation levels.
Branches of the right or left hepatic artery were selec-
tively or super-selectively catheterised using 5-F diagnostic
catheters with or without 3-F co-axial catheters in addition.
The peripheral vascular bed was first embolised with a
mixture of polyvinyl alcohol (PVA) particles of sizes rang-
ing between 250 and 1,180 μm followed by embolisation of
the branch vessel with platinum microcoils (Target
Therapeutics, Fremont, CA, USA) or steel macrocoils
(William Cook Europe A/S, Bjaerverskov, Denmark). With
the exception of one patient who underwent five embolisa-
tion sessions, only tertiary branches of the hepatic arteries
(and beyond) were embolised, leaving the central vessels
open. The vessels in the right and the left lobe were embol-
ised in separate sessions. During the procedure, the patient
received an infusion containing an analgesic, an anti-emetic
and a steroid. An embolisation session was concluded either
when the patient developed right upper quadrant or epigas-
tric pain or when the angiogram showed marked reduction
or disappearance of the peripheral telangiectasia in the por-
tion of the liver that was embolised. Prophylactic antibiotic
coverage was provided for at least 5 days following the
procedure and longer if clinically indicated. Analgesics
and anti-emetics were administered as and when necessary
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during and after every embolisation. Further procedural
details have been described in a previous publication [9].
The quality of life before HAE and at the end of follow-up
was assessed retrospectively in surviving patients with the
help of a modified SF 36 questionnaire in order to document
subjective patient response. Data assessed by the question-
naire included information relating to fatigability, pain and
general constitution, which were classified by the patients as
poor, unsatisfactory, satisfactory, good or excellent.
Statistical analysis
Continuous variables are expressed as means ± SD.
Comparison of cardiac output before treatment and at the
end of the observation period was performed applying
Student’s paired t-test and Fisher’s exact test (SPSS for
Windows 10.0; SPSS, Chicago, IL); P values<0.05 were
considered statistically significant.
Results
Patient demographics and pre-procedural symptomatology
(Table 1)
Of the 20 patients, 4 were men and 16 were women with ages
ranging between 29 and 72 years (mean 53.7±9.53 years).
The cardiac output was raised in all patients and ranged
between 7.4 l/min and 19.5 l/min (mean 11.84±3.22 l/min).
Cardiac failure/insufficiency with symptoms such as ear-
ly fatigue, limitation of physical activity, dyspnoea, orthop-
noea and pedal oedema was present in 16 patients.
Of the seven patients with therapy resistant abdominal
pain, two had abdominal angina presenting post-prandially
and five had capsular pain caused by hepatomegaly and
vascular congestion of the liver.
Ascites, oesophageal varices and pedal oedema as signs
of portal hypertension were present in four patients.
Three patients suffered from hepatic encephalopathy.
A combination of two of the manifestations stated above
was present in six patients and of three manifestations in
three patients.
Procedural complications (Table 2)
Post-interventional abdominal pain in the epigastric region
and/or in the right upper quadrant was experienced by all
but one patient. Under a combination of analgesics consist-
ing of metamizol, tramadol and opiates, the pain resolved
after 2 weeks in 14 patients and after 6 weeks in one patient.
Ischaemic cholecystitis and cholangitis were observed in
four patients; in addition, one of these patients developed an
acute pancreatitis, which, however, could be managed
conservatively. Focal areas of hepatic necrosis were noted
in three of these four patients with multiple biliary abscesses
and biliary sepsis in one of them (Fig. 1). All four under-
went cholecystectomy 12, 14, 18 and 28 weeks after the last
embolisation, with or without concomitant debridement of
areas of hepatic necrosis or partial hepatic resection. The
surgery was uneventful in three patients. On account of
post-operative biliomas, a cutaneous biliary fistula and re-
current bouts of biliary sepsis, the fourth patient was listed
for liver transplantation. However, on account of a Model of
End-stage Liver Disease (MELD) score of 10 at this stage,
transplantation was not performed. Following multiple per-
cutaneous drainages and antibiotic therapy, the patient un-
derwent complete clinical recovery and the MELD score
improved to 7.5; consequently, she was taken off the trans-
plantation list 14 months following HAE.
Thirty-day mortality (Table 1)
Two patients died within 30 days after HAE, giving a 30-day
mortality of 10 %. Both patients presented pre-terminally and
were in any case deemed unsuitable for liver transplantation
on account of severe co-morbidities; the HAE was carried out
as “ultima ratio” for lack of other therapy options.
The first patient presented with advanced biliary disease
with cirrhosis accompanied by severe hepatic encephalopa-
thy and portal hypertension; in addition, she suffered from
chronic tachy-arrhythmias, pleural effusions with marked
dyspnoea and pulmonary hypertension with a pulmonary
arterial pressure of 50 mmHg [cardiac insufficiency, New
York Heart Association (NYHA) IV]. She died of multi-
organ failure 23 days after the first embolisation.
The second patient had limited pulmonary reserve due to a
previous left-sided pneumonectomy; in addition, pulmonary
arteriovenous shunts and pulmonary hypertension were pres-
ent. She was admitted with cardiac insufficiency (NYHA IV)
and biliary disease with cirrhosis accompanied by encepha-
lopathy. Thirty days following the third embolisation, she died
of gastrointestinal bleeding and multiorgan failure.
Further deaths at follow-up (Table 1)
During follow-up, 4 further patients died of causes unrelated
to the HAE.
The first one responded well clinically to the HAE with a
fall in cardiac output from 17.3 l/min to 5.8 l/min, disap-
pearance of massive ascites and regression of oesophageal
varices from grade III to grade I. Seven months following
HAE, she was readmitted for critical variceal bleeding. She
died of post-operative sepsis following an unsuccessful at-
tempt to create a porto-systemic shunt.
In the second patient, the cardiac output fell from 14.0 l/
min to 8.8 l/min and the symptoms of cardiac insufficiency
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improved after HAE. A bout of grade III encephalopathy
accompanied by severe epistaxis led to multi-organ failure
and death 5 months after the HAE. At the final admission,
further invasive treatment in any form was refused by the
patient and her relatives.
The third patient died before completion of therapy. The
patient succumbed to complications of severe Parkinsonism
and of a fractured neck femur, which occurred before the
planned third HAE session.
The fourth patient died of post-operative complications
following hip surgery 36 months after successful HAE.
Clinical outcome (Table 1)
There was a transient increase of serum aminotransferases
following embolisation, which returned to pre-embolisation lev-
els at or shortly following discharge. Other than this, there was
no significant long-term impairment of liver synthetic function.
Two patients had intractable abdominal angina (caused
by a steal phenomeon) with severe resultant weight loss.
Following treatment, the abdominal angina resolved and the
patients gained 6 and 10 kg body weight respectively in the
year following the conclusion of therapy. One of them had















Before After Before After Before After Before After Before After
1 53 F 11.8 9.0
2 49 F ++ − 11.4 8.0
3 57 F 8.2 4.5
4 72 M 13.5 12.4 Died 3 months after 2




5 56 F ++ − 7.4 4.8
6 57 F + + 7.6 8.1 Died within 30 days after
third HAE
7 29 F +++ − 14.0 7.5 Two uncomplicated
pregnancies after
treatment
8 54 F + − 15.0 9.7
9 41 F + − 17.3 5.8 Died 7 months after
completion of HAE of
post-operative sepsis
following laparotomy
10 59 M ++ − 12.0 9.2
11 41 F +++ − 12.9 6.3
12 47 F 12.5 8.0
13 61 F 10.1 9.0 Died 36 months after
completion of HAE
following hip surgery
14 56 F + + + + 10.0 11.0 Died within 30 days after
first HAE
15 63 F ++ ± + − 7.5 5.5
16 52 F 10.7 8.0
17 50 M 19.5 15.0
18 67 M + + 14.0 8.8 Died 5 months after 3
sessions of HAE of
severe encephalopathy
and nasal bleeding
19 48 F ++ ± 9.1 4.2
20 61 F 12.3 7.7
Before pre-therapy; after post-therapy at end of follow-up; + present; − absent; ± occasionally present
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two uneventful pregnancies at the age of 34 and 38 years, 31
and 79 months after HAE respectively.
Of the five patients with capsular pain as a presenting feature,
three are presently free of pain without medication. Two further
patients have been successfully weaned off regular analgesics;
only occasional intake of oral analgesics is necessary.
The mean cardiac output reduced significantly (P<0.001)
from 11.84±3.22 l/min pre-treatment to 8.13±2.67 l/min at the
end of follow-up. Except in the two patients who died within
30 days after the first embolisation, symptoms arising from
cardiac failure resolved or improved markedly in all patients.
Of the four patients with portal hypertension, ascites and
oesophageal varices disappeared completely in two patients.
The third patient responded well to the HAE with a fall in
cardiac output, disappearance of massive ascites and regres-
sion of oesophageal varices. She however succumbed
7 months later to complications of surgical intervention for
critical variceal bleeding. The fourth patient died within
30 days of the procedure.
Worthy to note is that two patients developed de novo
signs of portal hypertension 18 months and 4 years after
HAE. The first one developed grade I–II oesophageal and
fundal varices without ascites. As the patient is asypmto-
matic, she is being managed conservatively at present. The
second patient developed grade I–II oesophageal varices
and therapy-refractory ascites 4 years after HAE. She un-
derwent successful liver transplantation and presently con-
tinues to be asymptomatic.
Analysis of the quality of life questionnaire showed that,
prior to therapy, the patients classified their condition on 21
counts as “poor” or “unsatisfactory” with regard to fatiga-
bility, pain and general condition. Following therapy, this
count fell to seven. In the group consisting of “satisfactory”,
“good” or “excellent”, 15 counts were noted pre-therapy;
this count improved to 29 post-therapy (Fig. 2).
Discussion
Therapy-related death occurring within 30 days following
HAE was observed in two patients. Both had severe co-
morbidities on account of which theywere in any case deemed
















5 56 F + + - Debridement of hepatic necrosis
- Cholecystectomy
2 47 F + + + - Cholecystectomy
- (Rest managed conservatively)
13 61 F + + - Debridement of hepatic necrosis
- Cholecystectomy
19 48 F + + + + - Debridement of hepatic necrosis
- Cholecystectomy
- Partial hepatic resection
+, present
Fig. 1 CT in the portal venous phase, axial section (a) and coronary
reconstruction (b) showing multiple biliary abscesses (arrows) and
hydrops of the gall bladder (arrowhead) 22 weeks following hepatic
artery embolisation (HAE)
Eur Radiol (2013) 23:951–957 955
unsuitable for liver transplantation. Amongst the comorbidites
in these two patients, pulmonary hypertension, cardiac failure
and hepatic encephalopathy resulting from biliary disease and
cirrhosis were common to both. Treatment of this set of pre-
terminal patients poses a problem to the transplant surgeon
and to the interventionist alike. In this respect, the HHT self-
help organisations could be of assistance in detecting and
treating the patients at an earlier stage.
The overall long-termmortality in our 20 patients amounted
to 30 %. This is comparable to the 20 % mortality reported by
Lerut and colleagues in 40 patients with liver transplantation
[11]; their peri-operative mortality was 17.5 % as compared to
the 10 % procedure-related mortality in our patients. Similarly,
of the six transplanted patients reported by Azoulay and col-
leagues, two died [12]. As opposed to this, Dupuis-Girod
reported a mortality of 8 % in 13 of their 753 patients
(1.7 %) who underwent liver transplantation [13].
It is worthy of mention that two of our four patients with
portal hypertension died and that three of the six patients who
died had signs of biliary disease with hepatic cirrhosis and
encephalopathy. The presence of portal hypertension and cir-
rhosis with encephalopathy could be poor prognostic factors
for patients undergoing HAE, especially if they are further
complicated by pulmonary hypertension and cardiac failure.
As is evident from 15 of our 20 patients, uncomplicated
post-procedural pain usually resolves within 2 to 6 weeks with
conservative treatment with analgesics such as metamizol,
tramadol and opiates.
Our procedure-related complication rate of 20 % com-
pares favourably with the 60 % complication rate reported
by Lerut and colleagues [11] as well as with the 54 % (7 of
13 patients) experienced by Dupuis-Girod [13]. Six of the
documented 35 patients in Lerut’s cohort required additional
surgery [11] as was the case in 4 of our 20 patients.
The main complications of HAE are ischaemic cholangi-
tis, ischaemic cholecystitis and focal biliary or hepatic ne-
crosis with or without biliary sepsis [6, 10].
Surgical intervention in the form of cholecystectomy and
partial liver resection was necessary in 4 of the 20 patients.
Attempts at optimising the HAE procedure should be aimed at
reducing these complications. A possible solution would be to
embolise smaller portions of the liver at each sitting and to
increase the interval between the embolisation sessions. This
would avoid injury to large portions of hepatic tissue at a time
Fig. 2 Subjective patient
assessment of clinical status
with regard to fatigability, pain
and general condition before (a)
and after (b) hepatic artery
embolisation (HAE)
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[10] and give the patient time to recover adequately from the
ischaemic insult of the previous procedure. Both of these in
turn could prevent the occurrence of widespread biliary sepsis
and acute liver failure leading to death [7, 14] or necessitating
emergency liver transplantation [6, 15].
Furthermore, during the procedure, it could be worth-
while to place the tip of the embolisation catheter securely
distal to the origin of the cystic artery to reduce the inci-
dence of ischaemic cholecystitis; with the large variety of
wide lumen micro-catheters available nowadays, this should
no longer pose any great difficulty.
The management of HHT patients with hepatic involve-
ment can be complex [1, 2]. As illustrated by Buscarini and
colleagues in 154 patients, hepatic involvement is not uncom-
mon in patients with HHT. In these patients, the course of the
disease is complicated in about 25 % of the patients who then
require treatment. As medical management occasionally sup-
plemented by cardioversion and radiofrequency catheter ab-
lation yield complete (63. 7 %) or partial (21. 8 %) response in
the majority of the patients, such management appears to be
the most appropriate primary treatment [1, 2]. Further invasive
therapy in the form of HAE or liver transplantation should be
considered in non-responders to medical management as well
as in those with unsatisfactory partial response.
Similar to liver transplantation, a good clinical response
with respect to amelioration of abdominal angina, capsular
pain and symptoms of cardiac decompensation or portal hy-
pertension can be expected at long-term follow-up after HAE.
The procedure-relatedmortality rates with both the procedures
are comparable, whereas complication rates are lower with
HAE. Should one be successful in further reducing the com-
plication rate with the methods suggested above, HAE would
become an even more attractive therapy option for treating
patients with HHT and symptomatic hepatic involvement, at
least till such time as the role of vascular endothelial growth
factor (VEGF) antagonists in the long-term treatment of these
patients becomes better defined [16–18]. This is especially
important as patient reluctance to undergomajor surgery in the
form of liver transplantation often influences the choice of
therapy. However, patients with concomitant portal hyperten-
sion and cirrhosis with encephalopathy, especially if further
complicated by pulmonary hypertension and cardiac failure,
could be a high-risk group for HAE. This subset of patients
could possibly benefit more from primary liver transplanta-
tion, should they be suitable for it.
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